Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis

Journal of Hepatology

Volumn 52, Issue 2, 2010, Pages 176-182

  Shim, Ju Hyun ^a   Lee, Han Chu ^a   Kim, Kang Mo ^a   Lim, Young Suk ^a   Chung, Young Hwa ^a   Lee, Yung Sang ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Decompensated cirrhosis; Efficacy; Entecavir; Hepatitis B virus

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHILD TURCOTTE PUGH SCORE; CHRONIC HEPATITIS; CLINICAL ASSESSMENT TOOL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; FEMALE; HAZARD RATIO; HEPATITIS B VIRUS; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE; MONOTHERAPY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SCORING SYSTEM; SEROCONVERSION; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 75349107764     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.11.007     Document Type: Article

References (30)

1. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61 (1988) 1942-1956
2. Bosch F.X., Ribes J., Cleries R., and Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9 (2005) 191-211 v
3. Lee H., and Kim C. Seroepidemiology of HBV and HCV in Korea: the decreasing prevalence rate of HBV infection after launching HB vaccination program. Int Hepatol Commun 5 (1996) 53-61
4. Kim C., Lee H., and Han C. Relative etiologic role of hepatitis B virus and hepatitis C virus in chronic liver diseases and hepatocellular carcinoma among age-specific groups in Korea: the possible presence of non-B, non-C agents. Seoul J Med 34 (1993) 27-33
5. de Jongh F.E., Janssen H.L., de Man R.A., Hop W.C., Schalm S.W., and van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 103 (1992) 1630-1635
6. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
7. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., and Chen C.J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
8. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
9. Chang T.T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.C., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
10. Hou J., Yin Y.K., Xu D., Tan D., Niu J., Zhou X., et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 47 (2008) 447-454
11. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007) 2576-2588
12. Lai C.L., Shouval D., Lok A.S., Chang T.T., Cheinquer H., Goodman Z., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006) 1011-1020
13. Keeffe E.B., Dieterich D.T., Han S.H., Jacobson I.M., Martin P., Schiff E.R., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 6 (2008) 1315-1341
14. Schiff E., Simsek H., Lee W.M., Chao Y.C., Sette Jr. H., Janssen H.L., et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 103 (2008) 2776-2783
15. Tenney D.J., Rose R.E., Baldick C.J., Pokornowski K.A., Eggers B.J., Fang J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49 (2009) 1503-1514
16. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
17. Child C.G., Turcotte J.G., and Kuwahara R. Surgery and porta hypertension. Major Probl Clin Surg 1 (1964) 1-85
18. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., and Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 (1973) 646-649
19. Yao F.Y., and Bass N.M. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 33 (2000) 301-307
20. Kapoor D., Guptan R.C., Wakil S.M., Kazim S.N., Kaul R., Agarwal S.R., et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 33 (2000) 308-312
21. Villeneuve J.P., Condreay L.D., Willems B., Pomier-Layrargues G., Fenyves D., Bilodeau M., et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 31 (2000) 207-210
22. Yao F.Y., Terrault N.A., Freise C., Maslow L., and Bass N.M. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 34 (2001) 411-416
23. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 50 (2009) 227-242
24. Hadziyannis S.J., and Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 34 (2001) 617-624
25. Fattovich G., Bortolotti F., and Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 48 (2008) 335-352
26. Yoo B.C., Park J.W., Kim H.J., Lee D.H., Cha Y.J., and Park S.M. Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea. J Hepatol 38 (2003) 98-103
27. Song B.C., Suh D.J., Lee H.C., Chung Y.H., and Lee Y.S. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32 (2000) 803-806
28. Kim J.H., Park J.W., Koh D.W., Lee W.J., and Kim C.M. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma. Liver Int 29 (2009) 203-207
29. Fontana R.J., Hann H.W., Perrillo R.P., Vierling J.M., Wright T., Rakela J., et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 123 (2002) 719-727
30. Bae S.H., Yoon S.K., Choi J.Y., Jang J.W., Cho S.H., Yang J.M., et al. Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis. J Gastroenterol Hepatol 20 (2005) 1527-1532